Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cryopreserved Platelet
Therapeutic Area : Hematology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cellphire Therapeutics CLPH-511 Fast Track Designation Granted
Details : CLPH-511 (frozen activated platelets) injectable suspension is being evaluated for the treatment of acute hemorrhage as an alternative to conventional platelets when not available or in short supply.
Product Name : CLPH-511
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Cryopreserved Platelet
Therapeutic Area : Hematology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Simcah Management
Deal Size : $15.0 million
Deal Type : Series A Financing
Cellphire Therapeutics, Inc. Closes $15 Million Series A Funding Round Led by Simcah Management
Details : This financing round enables Cellphire to expand and accelerate the development of Thrombosomes® and support the company's groundbreaking research and development projects in the areas of targeted drug delivery, anti-thrombotic reversal, and regenerativ...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 04, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Simcah Management
Deal Size : $15.0 million
Deal Type : Series A Financing